nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—ABCB1—ovarian cancer	0.187	1	CbGaD
Aripiprazole—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0325	0.0991	CbGbCtD
Aripiprazole—CYP3A7—Paclitaxel—ovarian cancer	0.0325	0.0991	CbGbCtD
Aripiprazole—ABCB1—Topotecan—ovarian cancer	0.0321	0.0977	CbGbCtD
Aripiprazole—CYP3A5—Paclitaxel—ovarian cancer	0.0244	0.0743	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0235	0.0716	CbGbCtD
Aripiprazole—CYP3A7—Docetaxel—ovarian cancer	0.0235	0.0716	CbGbCtD
Aripiprazole—ABCB1—Vinorelbine—ovarian cancer	0.0226	0.0688	CbGbCtD
Aripiprazole—CYP2D6—Vinorelbine—ovarian cancer	0.0213	0.0649	CbGbCtD
Aripiprazole—CYP3A4—Topotecan—ovarian cancer	0.0192	0.0585	CbGbCtD
Aripiprazole—CYP3A5—Docetaxel—ovarian cancer	0.0176	0.0537	CbGbCtD
Aripiprazole—ABCB1—Paclitaxel—ovarian cancer	0.0159	0.0484	CbGbCtD
Aripiprazole—CYP3A4—Vinorelbine—ovarian cancer	0.0135	0.0412	CbGbCtD
Aripiprazole—ABCB1—Docetaxel—ovarian cancer	0.0115	0.035	CbGbCtD
Aripiprazole—CYP3A4—Paclitaxel—ovarian cancer	0.00951	0.029	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—ovarian cancer	0.00856	0.0261	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—ovarian cancer	0.00806	0.0246	CbGbCtD
Aripiprazole—CHRM3—muscle of abdomen—ovarian cancer	0.00744	0.0767	CbGeAlD
Aripiprazole—CYP3A4—Docetaxel—ovarian cancer	0.00688	0.0209	CbGbCtD
Aripiprazole—HTR7—vein—ovarian cancer	0.00546	0.0562	CbGeAlD
Aripiprazole—H1F0—oviduct—ovarian cancer	0.00544	0.0561	CbGeAlD
Aripiprazole—CYP3A4—Doxorubicin—ovarian cancer	0.00513	0.0156	CbGbCtD
Aripiprazole—HTR2A—vein—ovarian cancer	0.0034	0.0351	CbGeAlD
Aripiprazole—HTR1E—myometrium—ovarian cancer	0.00294	0.0303	CbGeAlD
Aripiprazole—H1F0—myometrium—ovarian cancer	0.00174	0.0179	CbGeAlD
Aripiprazole—H1F0—embryo—ovarian cancer	0.00167	0.0173	CbGeAlD
Aripiprazole—DRD4—testis—ovarian cancer	0.00161	0.0166	CbGeAlD
Aripiprazole—CHRM5—epithelium—ovarian cancer	0.00158	0.0163	CbGeAlD
Aripiprazole—HTR1E—female gonad—ovarian cancer	0.00156	0.0161	CbGeAlD
Aripiprazole—H1F0—uterine cervix—ovarian cancer	0.00135	0.014	CbGeAlD
Aripiprazole—DRD5—female reproductive system—ovarian cancer	0.00131	0.0135	CbGeAlD
Aripiprazole—H1F0—decidua—ovarian cancer	0.00129	0.0133	CbGeAlD
Aripiprazole—HTR2B—myometrium—ovarian cancer	0.00125	0.0129	CbGeAlD
Aripiprazole—H1F0—endometrium—ovarian cancer	0.00122	0.0126	CbGeAlD
Aripiprazole—CHRM4—testis—ovarian cancer	0.00121	0.0125	CbGeAlD
Aripiprazole—DRD5—female gonad—ovarian cancer	0.00119	0.0123	CbGeAlD
Aripiprazole—H1F0—gonad—ovarian cancer	0.00114	0.0117	CbGeAlD
Aripiprazole—H1F0—uterus—ovarian cancer	0.00113	0.0116	CbGeAlD
Aripiprazole—H1F0—female reproductive system—ovarian cancer	0.00101	0.0105	CbGeAlD
Aripiprazole—KCNH2—myometrium—ovarian cancer	0.001	0.0103	CbGeAlD
Aripiprazole—ADRA2C—myometrium—ovarian cancer	0.000987	0.0102	CbGeAlD
Aripiprazole—HTR2B—uterine cervix—ovarian cancer	0.000976	0.0101	CbGeAlD
Aripiprazole—H1F0—bone marrow—ovarian cancer	0.000958	0.00987	CbGeAlD
Aripiprazole—HTR2B—decidua—ovarian cancer	0.000929	0.00958	CbGeAlD
Aripiprazole—H1F0—female gonad—ovarian cancer	0.000923	0.00952	CbGeAlD
Aripiprazole—H1F0—vagina—ovarian cancer	0.000917	0.00946	CbGeAlD
Aripiprazole—HTR2B—endometrium—ovarian cancer	0.000882	0.0091	CbGeAlD
Aripiprazole—HTR7—epithelium—ovarian cancer	0.000843	0.00869	CbGeAlD
Aripiprazole—H1F0—testis—ovarian cancer	0.000819	0.00844	CbGeAlD
Aripiprazole—HTR2B—uterus—ovarian cancer	0.000813	0.00838	CbGeAlD
Aripiprazole—ADRA1A—epithelium—ovarian cancer	0.000813	0.00838	CbGeAlD
Aripiprazole—HTR1B—female reproductive system—ovarian cancer	0.000812	0.00837	CbGeAlD
Aripiprazole—HRH1—myometrium—ovarian cancer	0.000802	0.00826	CbGeAlD
Aripiprazole—ADRA2A—myometrium—ovarian cancer	0.000787	0.00812	CbGeAlD
Aripiprazole—HTR1D—female reproductive system—ovarian cancer	0.000786	0.0081	CbGeAlD
Aripiprazole—KCNH2—uterine cervix—ovarian cancer	0.000778	0.00802	CbGeAlD
Aripiprazole—HTR2C—female reproductive system—ovarian cancer	0.000778	0.00802	CbGeAlD
Aripiprazole—ADRA2C—uterine cervix—ovarian cancer	0.000768	0.00792	CbGeAlD
Aripiprazole—ADRB1—female reproductive system—ovarian cancer	0.000764	0.00787	CbGeAlD
Aripiprazole—SLC6A4—female reproductive system—ovarian cancer	0.000738	0.00761	CbGeAlD
Aripiprazole—CHRM1—female reproductive system—ovarian cancer	0.000735	0.00758	CbGeAlD
Aripiprazole—ADRA2C—decidua—ovarian cancer	0.000732	0.00754	CbGeAlD
Aripiprazole—HTR2B—female reproductive system—ovarian cancer	0.000731	0.00754	CbGeAlD
Aripiprazole—KCNH2—endometrium—ovarian cancer	0.000704	0.00726	CbGeAlD
Aripiprazole—HTR7—gonad—ovarian cancer	0.000701	0.00723	CbGeAlD
Aripiprazole—ADRA2C—endometrium—ovarian cancer	0.000694	0.00716	CbGeAlD
Aripiprazole—HTR2B—vagina—ovarian cancer	0.000661	0.00682	CbGeAlD
Aripiprazole—CHRM3—female reproductive system—ovarian cancer	0.000658	0.00678	CbGeAlD
Aripiprazole—KCNH2—uterus—ovarian cancer	0.000649	0.00669	CbGeAlD
Aripiprazole—HTR2A—embryo—ovarian cancer	0.000644	0.00664	CbGeAlD
Aripiprazole—CYP3A5—uterine cervix—ovarian cancer	0.000643	0.00663	CbGeAlD
Aripiprazole—ADRA2C—uterus—ovarian cancer	0.00064	0.0066	CbGeAlD
Aripiprazole—HRH1—epithelium—ovarian cancer	0.000629	0.00649	CbGeAlD
Aripiprazole—HTR7—female reproductive system—ovarian cancer	0.000626	0.00645	CbGeAlD
Aripiprazole—HRH1—uterine cervix—ovarian cancer	0.000624	0.00643	CbGeAlD
Aripiprazole—ADRA2A—uterine cervix—ovarian cancer	0.000613	0.00632	CbGeAlD
Aripiprazole—CHRM3—female gonad—ovarian cancer	0.000598	0.00617	CbGeAlD
Aripiprazole—HRH1—decidua—ovarian cancer	0.000594	0.00613	CbGeAlD
Aripiprazole—H1F0—lymph node—ovarian cancer	0.000593	0.00612	CbGeAlD
Aripiprazole—ADRA2A—decidua—ovarian cancer	0.000584	0.00602	CbGeAlD
Aripiprazole—KCNH2—female reproductive system—ovarian cancer	0.000583	0.00601	CbGeAlD
Aripiprazole—HRH1—endometrium—ovarian cancer	0.000564	0.00582	CbGeAlD
Aripiprazole—ADRA2A—endometrium—ovarian cancer	0.000554	0.00571	CbGeAlD
Aripiprazole—KCNH2—bone marrow—ovarian cancer	0.00055	0.00568	CbGeAlD
Aripiprazole—CHRM3—testis—ovarian cancer	0.000531	0.00547	CbGeAlD
Aripiprazole—KCNH2—female gonad—ovarian cancer	0.000531	0.00547	CbGeAlD
Aripiprazole—KCNH2—vagina—ovarian cancer	0.000527	0.00544	CbGeAlD
Aripiprazole—HTR2A—epithelium—ovarian cancer	0.000525	0.00542	CbGeAlD
Aripiprazole—ADRA2C—female gonad—ovarian cancer	0.000523	0.0054	CbGeAlD
Aripiprazole—ADRA2C—vagina—ovarian cancer	0.00052	0.00536	CbGeAlD
Aripiprazole—ADRA2A—gonad—ovarian cancer	0.000514	0.0053	CbGeAlD
Aripiprazole—ADRA2A—uterus—ovarian cancer	0.000511	0.00527	CbGeAlD
Aripiprazole—HTR7—testis—ovarian cancer	0.000505	0.00521	CbGeAlD
Aripiprazole—DRD2—testis—ovarian cancer	0.000478	0.00492	CbGeAlD
Aripiprazole—KCNH2—testis—ovarian cancer	0.000471	0.00485	CbGeAlD
Aripiprazole—HRH1—female reproductive system—ovarian cancer	0.000467	0.00482	CbGeAlD
Aripiprazole—ADRA2C—testis—ovarian cancer	0.000464	0.00479	CbGeAlD
Aripiprazole—ADRA2A—female reproductive system—ovarian cancer	0.000459	0.00473	CbGeAlD
Aripiprazole—ABCB1—myometrium—ovarian cancer	0.000439	0.00452	CbGeAlD
Aripiprazole—CYP3A5—female gonad—ovarian cancer	0.000438	0.00452	CbGeAlD
Aripiprazole—HTR2A—gonad—ovarian cancer	0.000437	0.00451	CbGeAlD
Aripiprazole—CYP3A5—vagina—ovarian cancer	0.000435	0.00449	CbGeAlD
Aripiprazole—HTR2B—lymph node—ovarian cancer	0.000428	0.00441	CbGeAlD
Aripiprazole—HRH1—female gonad—ovarian cancer	0.000425	0.00438	CbGeAlD
Aripiprazole—HRH1—vagina—ovarian cancer	0.000423	0.00436	CbGeAlD
Aripiprazole—ABCB1—embryo—ovarian cancer	0.000422	0.00435	CbGeAlD
Aripiprazole—ADRA2A—female gonad—ovarian cancer	0.000418	0.00431	CbGeAlD
Aripiprazole—ADRA2A—vagina—ovarian cancer	0.000415	0.00428	CbGeAlD
Aripiprazole—HTR2A—female reproductive system—ovarian cancer	0.00039	0.00402	CbGeAlD
Aripiprazole—HRH1—testis—ovarian cancer	0.000377	0.00389	CbGeAlD
Aripiprazole—ADRA2A—testis—ovarian cancer	0.00037	0.00382	CbGeAlD
Aripiprazole—CYP3A4—female reproductive system—ovarian cancer	0.000361	0.00373	CbGeAlD
Aripiprazole—CYP2D6—female reproductive system—ovarian cancer	0.000356	0.00367	CbGeAlD
Aripiprazole—HTR2A—vagina—ovarian cancer	0.000353	0.00364	CbGeAlD
Aripiprazole—ABCB1—epithelium—ovarian cancer	0.000344	0.00355	CbGeAlD
Aripiprazole—ABCB1—uterine cervix—ovarian cancer	0.000341	0.00352	CbGeAlD
Aripiprazole—KCNH2—lymph node—ovarian cancer	0.000341	0.00352	CbGeAlD
Aripiprazole—ADRA2C—lymph node—ovarian cancer	0.000337	0.00347	CbGeAlD
Aripiprazole—ABCB1—decidua—ovarian cancer	0.000325	0.00335	CbGeAlD
Aripiprazole—CYP2D6—female gonad—ovarian cancer	0.000324	0.00334	CbGeAlD
Aripiprazole—HTR2A—testis—ovarian cancer	0.000315	0.00325	CbGeAlD
Aripiprazole—ABCB1—endometrium—ovarian cancer	0.000309	0.00318	CbGeAlD
Aripiprazole—CYP2D6—testis—ovarian cancer	0.000287	0.00296	CbGeAlD
Aripiprazole—ABCB1—gonad—ovarian cancer	0.000286	0.00295	CbGeAlD
Aripiprazole—ABCB1—uterus—ovarian cancer	0.000285	0.00293	CbGeAlD
Aripiprazole—HRH1—lymph node—ovarian cancer	0.000273	0.00282	CbGeAlD
Aripiprazole—ADRA2A—lymph node—ovarian cancer	0.000269	0.00277	CbGeAlD
Aripiprazole—ABCB1—female reproductive system—ovarian cancer	0.000256	0.00264	CbGeAlD
Aripiprazole—ABCB1—bone marrow—ovarian cancer	0.000241	0.00249	CbGeAlD
Aripiprazole—ABCB1—female gonad—ovarian cancer	0.000233	0.0024	CbGeAlD
Aripiprazole—ABCB1—vagina—ovarian cancer	0.000231	0.00239	CbGeAlD
Aripiprazole—ABCB1—testis—ovarian cancer	0.000206	0.00213	CbGeAlD
Aripiprazole—ABCB1—lymph node—ovarian cancer	0.00015	0.00154	CbGeAlD
Aripiprazole—Confusional state—Docetaxel—ovarian cancer	9.2e-05	0.000277	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Doxorubicin—ovarian cancer	9.14e-05	0.000276	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Epirubicin—ovarian cancer	9.13e-05	0.000275	CcSEcCtD
Aripiprazole—Anaphylactic shock—Docetaxel—ovarian cancer	9.13e-05	0.000275	CcSEcCtD
Aripiprazole—Oedema—Docetaxel—ovarian cancer	9.13e-05	0.000275	CcSEcCtD
Aripiprazole—Weight increased—Doxorubicin—ovarian cancer	9.11e-05	0.000275	CcSEcCtD
Aripiprazole—Epistaxis—Epirubicin—ovarian cancer	9.1e-05	0.000274	CcSEcCtD
Aripiprazole—Infection—Docetaxel—ovarian cancer	9.07e-05	0.000273	CcSEcCtD
Aripiprazole—Weight decreased—Doxorubicin—ovarian cancer	9.06e-05	0.000273	CcSEcCtD
Aripiprazole—Sinusitis—Epirubicin—ovarian cancer	9.05e-05	0.000273	CcSEcCtD
Aripiprazole—Hyperglycaemia—Doxorubicin—ovarian cancer	9.03e-05	0.000272	CcSEcCtD
Aripiprazole—Agranulocytosis—Epirubicin—ovarian cancer	9.01e-05	0.000272	CcSEcCtD
Aripiprazole—Pneumonia—Doxorubicin—ovarian cancer	8.98e-05	0.000271	CcSEcCtD
Aripiprazole—Shock—Docetaxel—ovarian cancer	8.98e-05	0.000271	CcSEcCtD
Aripiprazole—Nervous system disorder—Docetaxel—ovarian cancer	8.95e-05	0.00027	CcSEcCtD
Aripiprazole—Thrombocytopenia—Docetaxel—ovarian cancer	8.94e-05	0.000269	CcSEcCtD
Aripiprazole—Infestation NOS—Doxorubicin—ovarian cancer	8.93e-05	0.000269	CcSEcCtD
Aripiprazole—Infestation—Doxorubicin—ovarian cancer	8.93e-05	0.000269	CcSEcCtD
Aripiprazole—Tachycardia—Docetaxel—ovarian cancer	8.91e-05	0.000269	CcSEcCtD
Aripiprazole—Feeling abnormal—Paclitaxel—ovarian cancer	8.87e-05	0.000267	CcSEcCtD
Aripiprazole—Skin disorder—Docetaxel—ovarian cancer	8.86e-05	0.000267	CcSEcCtD
Aripiprazole—Bradycardia—Epirubicin—ovarian cancer	8.82e-05	0.000266	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.8e-05	0.000265	CcSEcCtD
Aripiprazole—Renal failure—Doxorubicin—ovarian cancer	8.78e-05	0.000265	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.75e-05	0.000264	CcSEcCtD
Aripiprazole—Haemoglobin—Epirubicin—ovarian cancer	8.71e-05	0.000263	CcSEcCtD
Aripiprazole—Stomatitis—Doxorubicin—ovarian cancer	8.7e-05	0.000262	CcSEcCtD
Aripiprazole—Jaundice—Doxorubicin—ovarian cancer	8.7e-05	0.000262	CcSEcCtD
Aripiprazole—Anorexia—Docetaxel—ovarian cancer	8.7e-05	0.000262	CcSEcCtD
Aripiprazole—Rhinitis—Epirubicin—ovarian cancer	8.69e-05	0.000262	CcSEcCtD
Aripiprazole—Conjunctivitis—Doxorubicin—ovarian cancer	8.68e-05	0.000262	CcSEcCtD
Aripiprazole—Urinary tract infection—Doxorubicin—ovarian cancer	8.68e-05	0.000262	CcSEcCtD
Aripiprazole—Haemorrhage—Epirubicin—ovarian cancer	8.66e-05	0.000261	CcSEcCtD
Aripiprazole—Hepatitis—Epirubicin—ovarian cancer	8.66e-05	0.000261	CcSEcCtD
Aripiprazole—Hypoaesthesia—Epirubicin—ovarian cancer	8.62e-05	0.00026	CcSEcCtD
Aripiprazole—Pharyngitis—Epirubicin—ovarian cancer	8.6e-05	0.000259	CcSEcCtD
Aripiprazole—Sweating—Doxorubicin—ovarian cancer	8.56e-05	0.000258	CcSEcCtD
Aripiprazole—Urinary tract disorder—Epirubicin—ovarian cancer	8.56e-05	0.000258	CcSEcCtD
Aripiprazole—Urticaria—Paclitaxel—ovarian cancer	8.55e-05	0.000258	CcSEcCtD
Aripiprazole—Oedema peripheral—Epirubicin—ovarian cancer	8.53e-05	0.000257	CcSEcCtD
Aripiprazole—Hypotension—Docetaxel—ovarian cancer	8.53e-05	0.000257	CcSEcCtD
Aripiprazole—Haematuria—Doxorubicin—ovarian cancer	8.51e-05	0.000257	CcSEcCtD
Aripiprazole—Connective tissue disorder—Epirubicin—ovarian cancer	8.51e-05	0.000257	CcSEcCtD
Aripiprazole—Body temperature increased—Paclitaxel—ovarian cancer	8.51e-05	0.000257	CcSEcCtD
Aripiprazole—Abdominal pain—Paclitaxel—ovarian cancer	8.51e-05	0.000257	CcSEcCtD
Aripiprazole—Urethral disorder—Epirubicin—ovarian cancer	8.49e-05	0.000256	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Doxorubicin—ovarian cancer	8.45e-05	0.000255	CcSEcCtD
Aripiprazole—Epistaxis—Doxorubicin—ovarian cancer	8.42e-05	0.000254	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—ovarian cancer	8.38e-05	0.000253	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—ovarian cancer	8.35e-05	0.000252	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—ovarian cancer	8.33e-05	0.000251	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Docetaxel—ovarian cancer	8.31e-05	0.000251	CcSEcCtD
Aripiprazole—Insomnia—Docetaxel—ovarian cancer	8.25e-05	0.000249	CcSEcCtD
Aripiprazole—Paraesthesia—Docetaxel—ovarian cancer	8.19e-05	0.000247	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—ovarian cancer	8.16e-05	0.000246	CcSEcCtD
Aripiprazole—Dyspnoea—Docetaxel—ovarian cancer	8.14e-05	0.000245	CcSEcCtD
Aripiprazole—Somnolence—Docetaxel—ovarian cancer	8.11e-05	0.000245	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—ovarian cancer	8.1e-05	0.000244	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—ovarian cancer	8.08e-05	0.000244	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—ovarian cancer	8.06e-05	0.000243	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—ovarian cancer	8.04e-05	0.000242	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—ovarian cancer	8.04e-05	0.000242	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—ovarian cancer	8.04e-05	0.000242	CcSEcCtD
Aripiprazole—Dyspepsia—Docetaxel—ovarian cancer	8.03e-05	0.000242	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—ovarian cancer	8.02e-05	0.000242	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—ovarian cancer	8.02e-05	0.000242	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—ovarian cancer	7.98e-05	0.00024	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—ovarian cancer	7.96e-05	0.00024	CcSEcCtD
Aripiprazole—Decreased appetite—Docetaxel—ovarian cancer	7.93e-05	0.000239	CcSEcCtD
Aripiprazole—Hypersensitivity—Paclitaxel—ovarian cancer	7.93e-05	0.000239	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—ovarian cancer	7.92e-05	0.000239	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—ovarian cancer	7.9e-05	0.000238	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.88e-05	0.000238	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—ovarian cancer	7.88e-05	0.000238	CcSEcCtD
Aripiprazole—Fatigue—Docetaxel—ovarian cancer	7.87e-05	0.000237	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—ovarian cancer	7.86e-05	0.000237	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—ovarian cancer	7.86e-05	0.000237	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—ovarian cancer	7.83e-05	0.000236	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—ovarian cancer	7.81e-05	0.000235	CcSEcCtD
Aripiprazole—Pain—Docetaxel—ovarian cancer	7.8e-05	0.000235	CcSEcCtD
Aripiprazole—Constipation—Docetaxel—ovarian cancer	7.8e-05	0.000235	CcSEcCtD
Aripiprazole—Chills—Epirubicin—ovarian cancer	7.77e-05	0.000234	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—ovarian cancer	7.73e-05	0.000233	CcSEcCtD
Aripiprazole—Asthenia—Paclitaxel—ovarian cancer	7.72e-05	0.000233	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—ovarian cancer	7.66e-05	0.000231	CcSEcCtD
Aripiprazole—Pruritus—Paclitaxel—ovarian cancer	7.62e-05	0.00023	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—ovarian cancer	7.59e-05	0.000229	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—ovarian cancer	7.54e-05	0.000227	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—ovarian cancer	7.54e-05	0.000227	CcSEcCtD
Aripiprazole—Feeling abnormal—Docetaxel—ovarian cancer	7.52e-05	0.000227	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—ovarian cancer	7.49e-05	0.000226	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—ovarian cancer	7.47e-05	0.000225	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Docetaxel—ovarian cancer	7.46e-05	0.000225	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—ovarian cancer	7.44e-05	0.000224	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—ovarian cancer	7.44e-05	0.000224	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—ovarian cancer	7.43e-05	0.000224	CcSEcCtD
Aripiprazole—Tension—Epirubicin—ovarian cancer	7.4e-05	0.000223	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—ovarian cancer	7.39e-05	0.000223	CcSEcCtD
Aripiprazole—Diarrhoea—Paclitaxel—ovarian cancer	7.37e-05	0.000222	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—ovarian cancer	7.33e-05	0.000221	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—ovarian cancer	7.3e-05	0.00022	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—ovarian cancer	7.27e-05	0.000219	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—ovarian cancer	7.25e-05	0.000219	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—ovarian cancer	7.24e-05	0.000218	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—ovarian cancer	7.22e-05	0.000218	CcSEcCtD
Aripiprazole—Body temperature increased—Docetaxel—ovarian cancer	7.21e-05	0.000217	CcSEcCtD
Aripiprazole—Abdominal pain—Docetaxel—ovarian cancer	7.21e-05	0.000217	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—ovarian cancer	7.19e-05	0.000217	CcSEcCtD
Aripiprazole—Dizziness—Paclitaxel—ovarian cancer	7.12e-05	0.000215	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—ovarian cancer	7.11e-05	0.000214	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—ovarian cancer	7.08e-05	0.000214	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—ovarian cancer	7.02e-05	0.000212	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—ovarian cancer	7e-05	0.000211	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—ovarian cancer	6.98e-05	0.00021	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—ovarian cancer	6.98e-05	0.00021	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—ovarian cancer	6.97e-05	0.00021	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—ovarian cancer	6.93e-05	0.000209	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—ovarian cancer	6.88e-05	0.000207	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—ovarian cancer	6.85e-05	0.000206	CcSEcCtD
Aripiprazole—Vomiting—Paclitaxel—ovarian cancer	6.85e-05	0.000206	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—ovarian cancer	6.83e-05	0.000206	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—ovarian cancer	6.8e-05	0.000205	CcSEcCtD
Aripiprazole—Rash—Paclitaxel—ovarian cancer	6.79e-05	0.000205	CcSEcCtD
Aripiprazole—Dermatitis—Paclitaxel—ovarian cancer	6.78e-05	0.000204	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—ovarian cancer	6.78e-05	0.000204	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—ovarian cancer	6.78e-05	0.000204	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—ovarian cancer	6.76e-05	0.000204	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—ovarian cancer	6.75e-05	0.000204	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—ovarian cancer	6.75e-05	0.000204	CcSEcCtD
Aripiprazole—Headache—Paclitaxel—ovarian cancer	6.74e-05	0.000203	CcSEcCtD
Aripiprazole—Hypersensitivity—Docetaxel—ovarian cancer	6.72e-05	0.000203	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—ovarian cancer	6.71e-05	0.000202	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—ovarian cancer	6.67e-05	0.000201	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—ovarian cancer	6.63e-05	0.0002	CcSEcCtD
Aripiprazole—Cough—Epirubicin—ovarian cancer	6.58e-05	0.000198	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—ovarian cancer	6.58e-05	0.000198	CcSEcCtD
Aripiprazole—Asthenia—Docetaxel—ovarian cancer	6.55e-05	0.000197	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—ovarian cancer	6.53e-05	0.000197	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—ovarian cancer	6.51e-05	0.000196	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—ovarian cancer	6.47e-05	0.000195	CcSEcCtD
Aripiprazole—Pruritus—Docetaxel—ovarian cancer	6.46e-05	0.000195	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—ovarian cancer	6.45e-05	0.000194	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—ovarian cancer	6.42e-05	0.000194	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—ovarian cancer	6.42e-05	0.000194	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—ovarian cancer	6.42e-05	0.000194	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—ovarian cancer	6.41e-05	0.000193	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—ovarian cancer	6.4e-05	0.000193	CcSEcCtD
Aripiprazole—Nausea—Paclitaxel—ovarian cancer	6.4e-05	0.000193	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.38e-05	0.000192	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—ovarian cancer	6.34e-05	0.000191	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—ovarian cancer	6.29e-05	0.00019	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—ovarian cancer	6.28e-05	0.000189	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—ovarian cancer	6.27e-05	0.000189	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—ovarian cancer	6.26e-05	0.000189	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—ovarian cancer	6.25e-05	0.000188	CcSEcCtD
Aripiprazole—Diarrhoea—Docetaxel—ovarian cancer	6.24e-05	0.000188	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—ovarian cancer	6.21e-05	0.000187	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—ovarian cancer	6.17e-05	0.000186	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—ovarian cancer	6.16e-05	0.000186	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—ovarian cancer	6.16e-05	0.000186	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—ovarian cancer	6.13e-05	0.000185	CcSEcCtD
Aripiprazole—Infection—Epirubicin—ovarian cancer	6.12e-05	0.000184	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—ovarian cancer	6.09e-05	0.000184	CcSEcCtD
Aripiprazole—Shock—Epirubicin—ovarian cancer	6.06e-05	0.000183	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—ovarian cancer	6.05e-05	0.000182	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—ovarian cancer	6.04e-05	0.000182	CcSEcCtD
Aripiprazole—Dizziness—Docetaxel—ovarian cancer	6.03e-05	0.000182	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—ovarian cancer	6.03e-05	0.000182	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—ovarian cancer	6.03e-05	0.000182	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—ovarian cancer	6.01e-05	0.000181	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—ovarian cancer	5.98e-05	0.00018	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—ovarian cancer	5.95e-05	0.000179	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—ovarian cancer	5.94e-05	0.000179	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—ovarian cancer	5.94e-05	0.000179	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—ovarian cancer	5.94e-05	0.000179	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—ovarian cancer	5.92e-05	0.000179	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.9e-05	0.000178	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—ovarian cancer	5.87e-05	0.000177	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—ovarian cancer	5.87e-05	0.000177	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—ovarian cancer	5.81e-05	0.000175	CcSEcCtD
Aripiprazole—Vomiting—Docetaxel—ovarian cancer	5.8e-05	0.000175	CcSEcCtD
Aripiprazole—Rash—Docetaxel—ovarian cancer	5.75e-05	0.000173	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—ovarian cancer	5.75e-05	0.000173	CcSEcCtD
Aripiprazole—Dermatitis—Docetaxel—ovarian cancer	5.75e-05	0.000173	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—ovarian cancer	5.74e-05	0.000173	CcSEcCtD
Aripiprazole—Headache—Docetaxel—ovarian cancer	5.72e-05	0.000172	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—ovarian cancer	5.7e-05	0.000172	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—ovarian cancer	5.7e-05	0.000172	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—ovarian cancer	5.66e-05	0.000171	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.61e-05	0.000169	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—ovarian cancer	5.6e-05	0.000169	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—ovarian cancer	5.59e-05	0.000168	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—ovarian cancer	5.58e-05	0.000168	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—ovarian cancer	5.57e-05	0.000168	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—ovarian cancer	5.56e-05	0.000168	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—ovarian cancer	5.53e-05	0.000167	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—ovarian cancer	5.53e-05	0.000167	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—ovarian cancer	5.51e-05	0.000166	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—ovarian cancer	5.49e-05	0.000165	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—ovarian cancer	5.47e-05	0.000165	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—ovarian cancer	5.43e-05	0.000164	CcSEcCtD
Aripiprazole—Nausea—Docetaxel—ovarian cancer	5.42e-05	0.000163	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—ovarian cancer	5.42e-05	0.000163	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—ovarian cancer	5.35e-05	0.000161	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—ovarian cancer	5.32e-05	0.00016	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.31e-05	0.00016	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—ovarian cancer	5.31e-05	0.00016	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—ovarian cancer	5.26e-05	0.000159	CcSEcCtD
Aripiprazole—Pain—Epirubicin—ovarian cancer	5.26e-05	0.000159	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.19e-05	0.000156	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—ovarian cancer	5.15e-05	0.000155	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—ovarian cancer	5.11e-05	0.000154	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—ovarian cancer	5.08e-05	0.000153	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—ovarian cancer	5.07e-05	0.000153	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—ovarian cancer	5.06e-05	0.000153	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—ovarian cancer	5.03e-05	0.000152	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—ovarian cancer	5.01e-05	0.000151	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—ovarian cancer	4.95e-05	0.000149	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.92e-05	0.000148	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—ovarian cancer	4.91e-05	0.000148	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—ovarian cancer	4.89e-05	0.000147	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—ovarian cancer	4.87e-05	0.000147	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—ovarian cancer	4.87e-05	0.000147	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—ovarian cancer	4.87e-05	0.000147	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—ovarian cancer	4.87e-05	0.000147	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—ovarian cancer	4.69e-05	0.000141	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.66e-05	0.00014	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—ovarian cancer	4.54e-05	0.000137	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—ovarian cancer	4.52e-05	0.000136	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—ovarian cancer	4.5e-05	0.000136	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—ovarian cancer	4.5e-05	0.000136	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—ovarian cancer	4.42e-05	0.000133	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—ovarian cancer	4.35e-05	0.000131	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—ovarian cancer	4.21e-05	0.000127	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—ovarian cancer	4.2e-05	0.000127	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—ovarian cancer	4.09e-05	0.000123	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—ovarian cancer	4.07e-05	0.000123	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—ovarian cancer	4.03e-05	0.000121	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—ovarian cancer	3.91e-05	0.000118	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—ovarian cancer	3.9e-05	0.000117	CcSEcCtD
Aripiprazole—Rash—Epirubicin—ovarian cancer	3.88e-05	0.000117	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—ovarian cancer	3.88e-05	0.000117	CcSEcCtD
Aripiprazole—Headache—Epirubicin—ovarian cancer	3.86e-05	0.000116	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—ovarian cancer	3.77e-05	0.000114	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—ovarian cancer	3.66e-05	0.00011	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—ovarian cancer	3.62e-05	0.000109	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—ovarian cancer	3.59e-05	0.000108	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—ovarian cancer	3.59e-05	0.000108	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—ovarian cancer	3.57e-05	0.000108	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—ovarian cancer	3.38e-05	0.000102	CcSEcCtD
Aripiprazole—CYP3A5—Metabolism—PTEN—ovarian cancer	3.58e-06	6.37e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	3.58e-06	6.37e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—ovarian cancer	3.58e-06	6.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	3.57e-06	6.36e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PTEN—ovarian cancer	3.57e-06	6.36e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—ovarian cancer	3.56e-06	6.34e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—ovarian cancer	3.56e-06	6.34e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PTEN—ovarian cancer	3.56e-06	6.34e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	3.55e-06	6.32e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	3.55e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MMP9—ovarian cancer	3.54e-06	6.31e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	3.54e-06	6.3e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	3.53e-06	6.29e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	3.53e-06	6.29e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	3.53e-06	6.29e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EGFR—ovarian cancer	3.53e-06	6.29e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	3.53e-06	6.29e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PTEN—ovarian cancer	3.52e-06	6.28e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	3.51e-06	6.26e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	3.51e-06	6.25e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—ovarian cancer	3.51e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—ovarian cancer	3.5e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—ovarian cancer	3.5e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	3.5e-06	6.24e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	3.5e-06	6.23e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	3.5e-06	6.23e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—ovarian cancer	3.5e-06	6.23e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—ovarian cancer	3.49e-06	6.22e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.49e-06	6.22e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.48e-06	6.21e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	3.48e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—ovarian cancer	3.48e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	3.47e-06	6.19e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	3.47e-06	6.18e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—ovarian cancer	3.47e-06	6.18e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—ovarian cancer	3.46e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—ovarian cancer	3.45e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	3.45e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—ovarian cancer	3.45e-06	6.15e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	3.44e-06	6.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	3.43e-06	6.12e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—ovarian cancer	3.43e-06	6.12e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	3.43e-06	6.11e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TYMS—ovarian cancer	3.42e-06	6.1e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	3.41e-06	6.07e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—ovarian cancer	3.41e-06	6.07e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—ovarian cancer	3.39e-06	6.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	3.38e-06	6.02e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	3.38e-06	6.02e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3.38e-06	6.02e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	3.38e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—ovarian cancer	3.38e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	3.36e-06	5.99e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	3.36e-06	5.98e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—ovarian cancer	3.36e-06	5.98e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—ovarian cancer	3.35e-06	5.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	3.35e-06	5.97e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—ovarian cancer	3.34e-06	5.95e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—ovarian cancer	3.34e-06	5.95e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—ovarian cancer	3.33e-06	5.94e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—ovarian cancer	3.31e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—ovarian cancer	3.31e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	3.3e-06	5.88e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—ovarian cancer	3.3e-06	5.87e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—ovarian cancer	3.29e-06	5.87e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—ovarian cancer	3.29e-06	5.86e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	3.28e-06	5.85e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	3.27e-06	5.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	3.27e-06	5.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	3.26e-06	5.81e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—ovarian cancer	3.26e-06	5.81e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NRAS—ovarian cancer	3.25e-06	5.8e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—ovarian cancer	3.25e-06	5.79e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	3.24e-06	5.77e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—ovarian cancer	3.23e-06	5.76e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—ovarian cancer	3.23e-06	5.76e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—ovarian cancer	3.23e-06	5.75e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	3.22e-06	5.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	3.22e-06	5.73e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	3.22e-06	5.73e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	3.21e-06	5.72e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—ovarian cancer	3.21e-06	5.72e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—ovarian cancer	3.21e-06	5.72e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—ovarian cancer	3.2e-06	5.7e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NRAS—ovarian cancer	3.2e-06	5.7e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—ovarian cancer	3.2e-06	5.7e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NRAS—ovarian cancer	3.19e-06	5.69e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—ovarian cancer	3.19e-06	5.69e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—ovarian cancer	3.19e-06	5.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	3.18e-06	5.67e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NRAS—ovarian cancer	3.18e-06	5.67e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	3.18e-06	5.67e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—ovarian cancer	3.18e-06	5.67e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NRAS—ovarian cancer	3.17e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	3.17e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—ovarian cancer	3.17e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—ovarian cancer	3.17e-06	5.64e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—ovarian cancer	3.15e-06	5.62e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—ovarian cancer	3.15e-06	5.61e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NRAS—ovarian cancer	3.14e-06	5.6e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	3.14e-06	5.6e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—ovarian cancer	3.14e-06	5.6e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	3.13e-06	5.58e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.12e-06	5.56e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MAPK3—ovarian cancer	3.12e-06	5.55e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—ovarian cancer	3.11e-06	5.54e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—ovarian cancer	3.09e-06	5.51e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	3.09e-06	5.5e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	3.07e-06	5.46e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	3.06e-06	5.46e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MAPK3—ovarian cancer	3.06e-06	5.45e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—ovarian cancer	3.05e-06	5.43e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	3.05e-06	5.43e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	3.04e-06	5.41e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	3.04e-06	5.41e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	3.04e-06	5.41e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—ovarian cancer	3.03e-06	5.4e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—ovarian cancer	3.02e-06	5.37e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	3.01e-06	5.36e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	3e-06	5.35e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—ovarian cancer	3e-06	5.35e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—ovarian cancer	2.98e-06	5.31e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—ovarian cancer	2.98e-06	5.3e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—ovarian cancer	2.98e-06	5.3e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—ovarian cancer	2.97e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MAPK1—ovarian cancer	2.96e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—ovarian cancer	2.96e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—ovarian cancer	2.96e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—ovarian cancer	2.96e-06	5.27e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—ovarian cancer	2.95e-06	5.26e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	2.95e-06	5.25e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.94e-06	5.24e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—ovarian cancer	2.94e-06	5.23e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	2.93e-06	5.22e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—ovarian cancer	2.93e-06	5.22e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—ovarian cancer	2.92e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—ovarian cancer	2.92e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	2.92e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	2.92e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—ovarian cancer	2.92e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	2.91e-06	5.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	2.91e-06	5.19e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MAPK1—ovarian cancer	2.91e-06	5.18e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—ovarian cancer	2.91e-06	5.18e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	2.9e-06	5.17e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—ovarian cancer	2.9e-06	5.17e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	2.89e-06	5.15e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—ovarian cancer	2.89e-06	5.15e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	2.86e-06	5.1e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—ovarian cancer	2.86e-06	5.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	2.86e-06	5.09e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	2.86e-06	5.09e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—ovarian cancer	2.85e-06	5.08e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	2.84e-06	5.05e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—ovarian cancer	2.83e-06	5.05e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—ovarian cancer	2.83e-06	5.05e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—ovarian cancer	2.82e-06	5.02e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	2.81e-06	5e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—ovarian cancer	2.8e-06	4.99e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	2.79e-06	4.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	2.79e-06	4.97e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—ovarian cancer	2.78e-06	4.96e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—ovarian cancer	2.77e-06	4.93e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CAV1—ovarian cancer	2.76e-06	4.91e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—ovarian cancer	2.76e-06	4.91e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—ovarian cancer	2.75e-06	4.91e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—ovarian cancer	2.75e-06	4.9e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—ovarian cancer	2.75e-06	4.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—ovarian cancer	2.74e-06	4.89e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—ovarian cancer	2.74e-06	4.88e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—ovarian cancer	2.73e-06	4.87e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—ovarian cancer	2.71e-06	4.83e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—ovarian cancer	2.71e-06	4.83e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—ovarian cancer	2.71e-06	4.83e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—ovarian cancer	2.71e-06	4.82e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—ovarian cancer	2.7e-06	4.81e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—ovarian cancer	2.7e-06	4.81e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	2.7e-06	4.81e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—ovarian cancer	2.7e-06	4.8e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—ovarian cancer	2.69e-06	4.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	2.65e-06	4.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	2.65e-06	4.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	2.62e-06	4.67e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—ovarian cancer	2.59e-06	4.62e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	2.58e-06	4.6e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—ovarian cancer	2.58e-06	4.6e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	2.57e-06	4.58e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—ovarian cancer	2.54e-06	4.53e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	2.53e-06	4.51e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	2.53e-06	4.5e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.52e-06	4.5e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	2.52e-06	4.48e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.51e-06	4.47e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—ovarian cancer	2.51e-06	4.47e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	2.51e-06	4.47e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	2.51e-06	4.46e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—ovarian cancer	2.5e-06	4.46e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—ovarian cancer	2.49e-06	4.43e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	2.49e-06	4.43e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	2.48e-06	4.42e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	2.48e-06	4.41e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—ovarian cancer	2.47e-06	4.4e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—ovarian cancer	2.45e-06	4.37e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—ovarian cancer	2.45e-06	4.36e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—ovarian cancer	2.44e-06	4.35e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—ovarian cancer	2.44e-06	4.34e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—ovarian cancer	2.43e-06	4.32e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—ovarian cancer	2.4e-06	4.28e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—ovarian cancer	2.4e-06	4.27e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—ovarian cancer	2.39e-06	4.26e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—ovarian cancer	2.38e-06	4.24e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—ovarian cancer	2.38e-06	4.24e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—ovarian cancer	2.34e-06	4.17e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—ovarian cancer	2.34e-06	4.16e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—ovarian cancer	2.33e-06	4.15e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—ovarian cancer	2.32e-06	4.14e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	2.32e-06	4.13e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	2.3e-06	4.1e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—ovarian cancer	2.3e-06	4.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	2.29e-06	4.08e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	2.28e-06	4.06e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—ovarian cancer	2.28e-06	4.06e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—ovarian cancer	2.25e-06	4.01e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—ovarian cancer	2.24e-06	3.99e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—ovarian cancer	2.24e-06	3.98e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—ovarian cancer	2.23e-06	3.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—ovarian cancer	2.23e-06	3.97e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—ovarian cancer	2.22e-06	3.96e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.21e-06	3.93e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—ovarian cancer	2.2e-06	3.92e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—ovarian cancer	2.19e-06	3.91e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	2.13e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.1e-06	3.74e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.07e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.06e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—ovarian cancer	2.06e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—ovarian cancer	2.06e-06	3.66e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—ovarian cancer	2.05e-06	3.65e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—ovarian cancer	2.04e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—ovarian cancer	2.03e-06	3.62e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	2.02e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.92e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.9e-06	3.39e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.88e-06	3.35e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.79e-06	3.2e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—ovarian cancer	1.66e-06	2.96e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—ovarian cancer	1.56e-06	2.77e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—ovarian cancer	1.47e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.17e-06	2.09e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—ovarian cancer	9.59e-07	1.71e-05	CbGpPWpGaD
